Racial and ethnic disparities in the uptake of SGLT2is and GLP-1RAs among Medicare beneficiaries with type 2 diabetes and heart failure, atherosclerotic cardiovascular disease and chronic kidney disease, 2013–2019
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index; 15 of the 22 sources its claims cite were checked for support.
Abstract
This retrospective Medicare study examined racial and ethnic disparities in initiation of SGLT2is and GLP-1RAs among older adults with type 2 diabetes across cardiorenal-risk subgroups.
Overview
CoChat Summary
TL;DR
In a retrospective cohort of Medicare fee-for-service beneficiaries aged 65+ with type 2 diabetes, Black participants had lower uptake of SGLT2 inhibitors and GLP-1 receptor agonists than White participants, and Hispanic participants had lower GLP-1RA uptake and some lower SGLT2i uptake depending on cohort. These disparities narrowed over 2013–2019 but did not disappear by 2019.
Key findings
- The final cohort included 838,361 glucose-lowering therapy initiation episodes: 152,214 with heart failure (HF), 412,890 with ASCVD, 154,849 with CKD, and 350,707 with no recorded cardiorenal conditions.
- Compared with White participants, Black participants had lower adjusted odds of initiating SGLT2is across all cohorts: HF OR 0.65, ASCVD OR 0.67, CKD OR 0.68, and no cardiorenal conditions OR 0.76.
- For Black participants, SGLT2i disparities attenuated from 50–60% lower odds in 2013 to 17–18% lower odds in 2019; similar adjusted disparities were seen for GLP-1RA initiation (HF OR 0.67, ASCVD OR 0.67, CKD OR 0.70, no cardiorenal conditions OR 0.71).
- Hispanic participants had similar adjusted odds of SGLT2i initiation to White participants in the HF and CKD cohorts, but lower odds in ASCVD (OR 0.94) and no cardiorenal conditions (OR 0.93); Hispanic participants had lower GLP-1RA initiation in all cohorts (ORs 0.89, 0.84, 0.84, 0.75).
- Black and Hispanic participants had higher odds of initiating DPP4 inhibitors than White participants; the paper reports HF 1.25, ASCVD 1.36, and CKD 1.32 for Hispanic participants, and says the same pattern held for Black participants.
Methods
- Retrospective cohort study using 2013–2019 Medicare fee-for-service Part D data; eligible participants were ≥65 years with type 2 diabetes, continuous enrollment for at least 1 year, and no prior use of the study medication in the baseline period.
- Participants were grouped into four non-mutually exclusive cohorts: HF, ASCVD, CKD, or no recorded cardiorenal conditions; race/ethnicity was classified as non-Hispanic White, non-Hispanic Black, Hispanic, or other.
- Main analysis used multinomial logistic regression to model initiation of SGLT2is, GLP-1RAs, DPP4is, or sulfonylureas, with sulfonylureas as the reference; models adjusted for demographic, clinical, and county-level social vulnerability factors, and analyses were stratified by cohort and calendar year.
Limitations
- The paper states that the 365-day washout may have missed prior use before baseline, that social vulnerability was measured at county level rather than individual level, that the findings are generalizable only to older Medicare fee-for-service beneficiaries, that formulary differences could not be accounted for, and that data on diabetes duration, disease control, and specialist visits were unavailable.
- The study ended in 2019, so it could not assess more recent changes after 2019/2020 guideline updates or the impact of COVID-19.
- Evident from the text: the “other race and ethnicity” group combined several populations and people with missing race data, which limited more granular assessment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Temporal patterns (2013–2019) in the proportions of new initiations of SGLT2is by race and ethnicity and cardiorenal condition: (a) comorbid HF; (b) comorbid ASCVD; (c) comorbid CKD; (d) no comorbid cardiorenal conditions. 1: EMPA-REG OUTCOME trial results published, highlighting the cardiovascular benefits of SGLT2is [6]. 2: ADA guideline shifts, indicating SGLT2is and GLP1-RAs as preferred therapies for individuals with type 2 diabetes and comorbid cardiovascular conditions [36]. 3: CREDENCE trial results published, highlighting SGLT2i benefits in CKD [37]](https://figures.cochat.ai/paper-figures/98b4bd87d7d54542a6532a1ca16a2539/racial-and-ethnic-disparities-in-the-uptake-of-sglt2is-and-glp-1ras-among-figure-1.jpg)
![Fig. 2 Temporal patterns (2013–2019) in the proportions of new initiations of GLP1 RAs by race and ethnicity and cardiorenal condition: (a) comorbid HF; (b) comorbid ASCVD; (c) comorbid CKD; (d) no comorbid cardiorenal conditions. 1: LEADER and SUSTAIN-6 trial results published, highlighting the cardiovascular benefits of GLP1-RAs [38, 39]. 2: ADA guideline shifts, indicating SGLT2is and GLP1-RAs as preferred therapies for individuals with type 2 diabetes and comorbid cardiovascular conditions [36]. 3: REWIND trial results published, highlighting the cardiovascular benefits of GLP-1RAs [40]](https://figures.cochat.ai/paper-figures/45c3a62d6d04457aba08de46e86f46d1/racial-and-ethnic-disparities-in-the-uptake-of-sglt2is-and-glp-1ras-among-figure-2.jpg)


Verification
Claims the paper makes
5 Valid · 2 Not valid · 2 Not checked · 49 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Despite consensus recommendations and accumulating clinical evidence, the adoption of SGLT2is and GLP-1RAs has been slow in those with type 2 diabetes and comorbid cardiorenal conditions [10, 11].”
§ Racial and ethnic disparities in the uptake of SGLT2is and GLP-1RAs among Medicare beneficiaries with type 2 diabetes and heart failure, atherosclerotic cardiovascular disease and chronic kidney disease, 2013–2019 > Introduction
What the sources say
- Supportedcites [10] Liaw J, Harhay M, Setoguchi S, Gerhard T, Dave CV (2022) Trends in prescribing preferences for antidiabetic medications among patients with type 2 diabetes in the U.K. with and without chronic kidney disease, 2006–2020. Diabetes Care 45(10):2316–2325. https://doi.org/10.2337/dc22-0224 source
The Conclusions (page not provided) report slower uptake of SGLT2is among patients with type 2 diabetes and CKD than among those without CKD, despite evidence and guidelines recommending their use. They also report that GLP-1RA prescribing remained minimal throughout the study period, regardless of CKD status. This supports the claim for the comorbid kidney-disease population studied. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [11] Dave CV, Schneeweiss S, Wexler DJ, Brill G, Patorno E (2020) Trends in clinical characteristics and prescribing preferences for SGLT2 inhibitors and GLP-1 receptor agonists, 2013–2018. Diabetes Care 43(4):921–924. https://doi.org/10.2337/dc19-1943 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After adjusting for the association of age, sex, SVI and other clinical characteristics, and using SUs as the reference category, Black participants with HF, ASCVD, CKD and no cardiorenal conditions had 35% (OR 0.65, 95% CI 0.61, 0.68), 33% (OR 0.67, 95% CI 0.64, 0.69), 32% (OR 0.68, 95% CI 0.64, 0.72) and 24% (OR 0.76, 95% CI 0.74, 0.79) lower odds of initiating SGLT2is, respectively, than White”
§ Racial and ethnic disparities in the uptake of SGLT2is and GLP-1RAs among Medicare beneficiaries with type 2 diabetes and heart failure, atherosclerotic cardiovascular disease and chronic kidney disease, 2013–2019 > Results > Adjusted ORs for medication initiation for Black vs White participants
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although the use of DPP4is and SUs declined in all four cardiorenal cohorts over the study period, the decline in DPP4i use was less pronounced among Black and Hispanic participants (ESM Figs 2 and 3; ESM Tables 5 and 6).”
§ Racial and ethnic disparities in the uptake of SGLT2is and GLP-1RAs among Medicare beneficiaries with type 2 diabetes and heart failure, atherosclerotic cardiovascular disease and chronic kidney disease, 2013–2019 > Results > Overall medication initiation trends by race and ethnicity
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Initiation rates of SGLT2is were comparable between Hispanic and White participants.”
§ Racial and ethnic disparities in the uptake of SGLT2is and GLP-1RAs among Medicare beneficiaries with type 2 diabetes and heart failure, atherosclerotic cardiovascular disease and chronic kidney disease, 2013–2019 > Results > Overall medication initiation trends by race and ethnicity
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the sensitivity analyses adjusting only for age and sex, the observed disparities were less pronounced (ESM Tables 9 and 10), indicating that the additional adjustments for clinical and other characteristics in the fully adjusted models resulted in the increased disparities observed.”
§ Racial and ethnic disparities in the uptake of SGLT2is and GLP-1RAs among Medicare beneficiaries with type 2 diabetes and heart failure, atherosclerotic cardiovascular disease and chronic kidney disease, 2013–2019 > Results > Adjusted ORs for medication initiation for Black vs White participants
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
34 more claims
Create a free account to see all 58 claims and every source verdict.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 9
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Similarly, Medicare analyses from 2013-2019 demonstrate persistent racial and ethnic disparities in use of GLP-1 RAs and SGLT2is across comorbid conditions, including heart failure and chronic kidney disease [29].”
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“In the sensitivity analyses adjusting only for age and sex, the observed disparities were less pronounced (ESM Tables 9 and 10), indicating that the additional adjustments GLP1-RAs [38, 39].”
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655 · cited 1×
“…and glucagon-like peptide-1 receptor antagonists (GLP-1RAs) have demonstrated benefits in preventing deleterious cardiorenal endpoints among individuals with type 2 diabetes, shifting disease management from a glucocentric approach to one that prioritises long-term cardiorenal health [5–7].”
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Epidemiology of Diabetes and Diabetes-Related Complications
Deshpande, A. D., Harris-Hayes, M., & Schootman, M. (2008) · Physical Therapy · doi:10.2522/ptj.20080020 · Cited by 1,773 · cited 1×
“…conditions, coupled with the micro-and macro-vascular consequences of chronic unmitigated hypergly-caemia, more than 35% of individuals with type 2 diabetes are co-diagnosed with atherosclerotic cardiovascular disease (ASCVD), congestive heart failure (HF) or chronic kidney disease (CKD) [1, 2].”
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555 · cited 1×
“Currently, these guidelines recommend SGLT2is and GLP-1RAs as the preferred therapy among individuals with type 2 diabetes and comorbid ASCVD or HF, and SGLT2is among those with comorbid CKD [8, 9].”
Fox, C. S., Matsushita, K., Woodward, M., Bilo, H. J., Chalmers, J., Heerspink, H. J. L., Lee, B. J., Perkins, R. M., Rossing, P., Sairenchi, T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61350-6 · Cited by 1,401 · cited 1×
“Compared with diabetes alone, the co-occurrence of cardiorenal conditions augurs a clinical course characterised by accelerated disease progression, excess healthcare spending and increased risk of all-cause mortality [3, 4].”
6. Glycemic Targets: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s006 · Cited by 762 · cited 1×
“2: ADA guideline shifts, indicating SGLT2is and GLP1-RAs as preferred therapies for individuals with type 2 diabetes and comorbid cardiovascular conditions [36].”
Cited by
Jack, G. A., Avenatti, E., Kashyap, S. R., & Sadhu, A. R. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf301 · Cited by 9
Prior Authorization Requirements and Prescription Fill Patterns Among Patients With Heart Failure
Mukhopadhyay, A., Adhikari, S., Li, X., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102583 · Cited by 5
Tailoring interventions to close gaps in diabetes mellitus care
Diaz-Thomas, A., Cabrera, S. M., Pereira, R. I., & Iyer, P. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01217-6 · Cited by 6
“These medications have revolutionized T2DM management, demonstrating high glucose-lowering effects and weight loss, renal protection, and cardioprotective effects 125 .”
Obi, M. F., Ahmad, S., & Ezechukwu, K. (2026) · Cureus · doi:10.7759/cureus.106266 · Cited by 1
“Similarly, Medicare analyses from 2013-2019 demonstrate persistent racial and ethnic disparities in use of GLP-1 RAs and SGLT2is across comorbid conditions, including heart failure and chronic kidney disease [29].”
Porterfield, L. R., Nadeem, S., Swanson, D., Hayek, S. S., & Vaughan, E. M. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01448-6 · Cited by 2
“Use of GLP-1RAs and SGLT2is is influenced by cost, insurance coverage, access to care, and structural barriers, with lower use observed among socioeconomically disad-vantaged individuals and racial and ethnic minority groups [56, 59, 60 ].”
Metadata
- Authors
- Wang, E., Patorno, E., Khosrow-Khavar, F., Crystal, S., & Dave, C. V.
- Affiliations
- Rutgers, The State University of New Jersey (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Wang, Eric
- Dave, Chintan V.
- Venue
- Diabetologia
- Published
- 2024-11-08
- Volume
- 68
- Issue
- 1
- Pages
- 94-104
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC11663158
- OpenAlex
- W4404186491
- Semantic Scholar
- c3e0be23fc9fc11dc9066c11b1c8f749461f7210
- Cited by
- 14
- References
- 40
- Citations by year
- 2026: 11 · 2025: 3
- FWCI
- 4.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Diabetologia (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- NIH (1R01HL163163)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- racial and ethnic disparities, SGLT2 inhibitors, GLP-1 receptor agonists, type 2 diabetes, heart failure, atherosclerotic cardiovascular disease, chronic kidney disease, Medicare beneficiaries, older adults, black-white disparities, DPP-4 inhibitors, sulfonylureas
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, White, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Aged, 80 and over, Black or African American, Diabetes Mellitus, Type 2, Ethnicity, Female, Medicare, Heart Failure, Hispanic or Latino, Humans, Male, Retrospective Studies, United States, Atherosclerosis, Renal Insufficiency, Chronic, Healthcare Disparities
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.